Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aytu Bioscience Inc (AYTU)

Aytu Bioscience Inc (AYTU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,195
  • Shares Outstanding, K 120,261
  • Annual Sales, $ 7,320 K
  • Annual Income, $ -27,130 K
  • 60-Month Beta -0.12
  • Price/Sales 23.82
  • Price/Cash Flow N/A
  • Price/Book 1.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +76,946.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +28.39%
on 04/23/20
2.1300 -28.87%
on 04/27/20
+0.2750 (+22.18%)
since 04/22/20
3-Month
0.3352 +351.97%
on 03/09/20
2.9900 -49.33%
on 03/10/20
+0.7620 (+101.20%)
since 02/21/20
52-Week
0.3352 +351.97%
on 03/09/20
2.9900 -49.33%
on 03/10/20
-0.4750 (-23.87%)
since 05/22/19

Most Recent Stories

More News
Aytu Bioscience, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

AYTU : 1.5150 (+4.48%)
Aytu BioScience Reports Third Quarter Fiscal 2020 Financial Results

INNV : 1.2300 (+6.03%)
AYTU : 1.5150 (+4.48%)
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

AYTU : 1.5150 (+4.48%)
Thinking about buying stock in AMC Entertainment, Carnival Corp, OraSure Technologies, Inovio Pharmaceuticals, or Aytu Bioscience?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, CCL, OSUR, INO, and AYTU.

AMC : 4.58 (-1.08%)
AC : 39.94 (+1.94%)
AYTU : 1.5150 (+4.48%)
CCL : 14.46 (-0.96%)
INO : 14.08 (-1.12%)
OSUR : 14.87 (+3.34%)
Aytu Bioscience Inc (AYTU) Outpaces Stock Market Gains: What You Should Know

Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.

AYTU : 1.5150 (+4.48%)
Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update

ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient...

AYTU : 1.5150 (+4.48%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aytu BioSciences, Inc. - AYTU

Pomerantz LLP is investigating claims on behalf of investors of Aytu BioSciences, Inc. ("Aytu" or the "Company") (NASDAQ: AYTU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AYTU : 1.5150 (+4.48%)
Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AYTU : 1.5150 (+4.48%)
Aytu Bioscience, Inc. (AYTU) Gains As Market Dips: What You Should Know

Aytu Bioscience, Inc. (AYTU) closed at $1.64 in the latest trading session, marking a +1.23% move from the prior day.

AYTU : 1.5150 (+4.48%)
Aytu BioScience Announces China Export Clearance of Company's COVID-19 IgG/IgM Rapid Test

500,000 Rapid Tests Cleared for Shipment to Company's Warehouse

AYTU : 1.5150 (+4.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AYTU with:

Business Summary

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual...

See More

Key Turning Points

2nd Resistance Point 1.5717
1st Resistance Point 1.5433
Last Price 1.5150
1st Support Level 1.4633
2nd Support Level 1.4117

See More

52-Week High 2.9900
Fibonacci 61.8% 1.9759
Fibonacci 50% 1.6626
Last Price 1.5150
Fibonacci 38.2% 1.3493
52-Week Low 0.3352

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar